PipelineReview.com - Therapeutic Proteins La Merie Publishing

Show Cart

La Merie Publishing

Results 11 - 11 of 11

Aug 2009 Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis

Start
Prev
1
2
Next
End

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

DLL3-Targeted Immunotherapy Candidates Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing